Veracyte (VCYT) Liabilities and Shareholders Equity (2012 - 2026)

Veracyte has reported Liabilities and Shareholders Equity for 15 years, with the latest figure at $1.5 billion in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $1.5 billion, up 10.58% year-over-year; the trailing twelve-month figure through Jun 2026 was $5.7 billion (up 8.83% YoY), and the FY2025 annual result was $1.4 billion, up 8.15% from the prior year.
• Liabilities and Shareholders Equity grew to $1.5 billion in Q2 2026, from $1.4 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.5 billion in Q2 2026 and troughed at $1.1 billion in Q4 2023.
• A 5-year average of $1.3 billion and a median of $1.2 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity fell 5.09%; it then rose 16.6% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.2 billion in 2022, then decreased by 3.59% to $1.1 billion in 2023, then rose by 16.6% to $1.3 billion in 2024, then advanced by 8.15% to $1.4 billion in 2025, then climbed by 5.71% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.5 billion in Q2 2026, $1.4 billion in Q1 2026, and $1.4 billion in Q4 2025.